M Hanefeld, P Brunetti, GH Schernthaner, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—HbA 1c was reduced by 1.20% in the SU plus pioglitazone group and
1.36% in the SU plus metformin group, and fasting plasma glucose was reduced by
2.2 and 2.3 mmol/l in the respective groups. Fasting insulin levels were ... Cited by 98 - Related articles - BL Direct - All 5 versions
DR Matthews, BH Charbonnel, M Hanefeld, P … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 89 - Related articles - All 3 versions
- ►endojournals.org G Schernthaner, DR Matthews, B Charbonnel, … - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc Pioglitazone increases the insulin sensitivity of peripheral tissues and may
provide an alternative first-line treatment for type 2 diabetes. This study
compared metabolic control in drug-naive type 2 diabetes patients given ... Cited by 91 - Related articles - All 6 versions
B Charbonnel, G Schernthaner, P Brunetti, … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: The aim of this analysis was to examine the long-term
effects of pioglitazone or gliclazide addition to failing metformin monotherapy
and pioglitazone or metformin addition to failing sulphonylurea monother- ... Cited by 97 - Related articles - All 5 versions
MH Tan, A Baksi, B Krahulec, P Kubalski, A … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This was a randomized, multicenter, double-blind,
double-dummy, parallel-group, 2-year study. Approximately 600 patients from 98
centers participated. Eligible patients had completed a previous 12-month ... Cited by 51 - Related articles - All 6 versions
S Nagasaka, Y Aiso, K Yoshizawa, S … - Diabetic medicine, 2004 - interscience.wiley.com Methods Seventy-eight Japanese subjects with Type 2 diabetes mellitus poorly
controlled with sulphonylureas [38 men and 40 women, aged 57 ± 9 years, body
mass index 25.2 ± 1.4 kg/m 2 , and HbA 1c 8.3 ± 0.6% (means ± sd)] were ... Cited by 27 - Related articles - BL Direct - All 4 versions
MH Tan, D Johns, J Strand, J Halse, S … - Diabetic Medicine, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 38 - Related articles - BL Direct - All 6 versions
G Derosa, AFG Cicero, A Gaddi, PD Ragonesi, … - Diabetes research and clinical practice, 2005 - Elsevier A total of 87 completed the study (pioglitazone n = 45 or rosiglitazone n = 42).
Body mass index increased after 12 months compared to baseline (p < 0.05) in
both groups. A significant decrease in glycated haemoglobin (HbA 1c ) was ... Cited by 61 - Related articles - All 9 versions
MS Kipnes, A Krosnick, MS Rendell, JW Egan … - The American journal of medicine, 2001 - Elsevier RESULTS: Patients receiving pioglitazone + sulfonylurea had significant (P
<0.05) decreases from baseline in HbA 1C and fasting plasma glucose levels
compared with patients treated with placebo + sulfonylurea. As compared ... Cited by 235 - Related articles - BL Direct - All 8 versions
